Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2008
03/13/2008WO2008029371A1 Pyridin-4-yl derivatives as immunomodulating agents
03/13/2008WO2008029370A1 Pyridin-3-yl derivatives as immunomodulating agents
03/13/2008WO2008029351A2 A modified release formulation comprising amoxicillin and clavulanate
03/13/2008WO2008029306A2 Thiophene derivatives as s1p1/edg1 receptor agonists
03/13/2008WO2008029282A2 Aqueous formulation comprising an antitumor agent
03/13/2008WO2008029271A2 Ceacam based antibacterial agents
03/13/2008WO2008029266A1 Stearoyl coa desaturase inhibitors
03/13/2008WO2008029264A2 Method of treating bone cancer
03/13/2008WO2008029208A1 Use of polyols to obtain stable polymorphous forms of rifaximin
03/13/2008WO2008029199A1 Positively charged water-soluble prodrugs of n-arylanthranilic acids with very fast skin penetration rate
03/13/2008WO2008029168A2 Treatment of duchenne muscular dystrophy
03/13/2008WO2008029152A2 Treatment of duchenne muscular dystrophy
03/13/2008WO2008029136A1 Pharmaceutical composition and method for cancer treatment based on combinational use of conventional or plant-derived anticancer agents and geranium oil or compounds thereof
03/13/2008WO2008029096A2 P53 activating benzoyl urea and benzoyl thiourea compounds
03/13/2008WO2008028966A1 Crystalline forms of 1,6-bis [3-(3-carboxymethylphenyl)-4-(2-alpha-d-mannopyranosyl-oxy)-phenyl] hexane
03/13/2008WO2008028965A2 Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, preparation and uses thereof
03/13/2008WO2008028963A2 Calreticulin for its use as a medication for the treatment of cancer in a mammal
03/13/2008WO2008028959A1 Crystalline form of moxifloxacin hydrochloride
03/13/2008WO2008028958A1 Cyclic sulfones useful as mitochondrial sodium-calcium exchangers
03/13/2008WO2008028951A1 Tasteless nutritional supplement containing free amino acids
03/13/2008WO2008028937A1 N-biaryl (hetero) arylsulphonamide derivatives useful in the treatment of diseases mediated by lymphocytes interactions
03/13/2008WO2008028935A2 Pyridinyl-pyrimidine derivatives useful as potassium channel modulating agents
03/13/2008WO2008028934A1 Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof
03/13/2008WO2008028928A1 Novel combination of agents for the treatment of hiv-associated adipose redistribution syndrome (hars)
03/13/2008WO2008028914A1 Combination treatment for diabetes mellitus
03/13/2008WO2008028903A2 Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
03/13/2008WO2008028860A1 Benzotriazole kinase modulators
03/13/2008WO2008028691A1 N-(1-hetarylpiperidin-4-yl)(het)arylamides as ep2 receptor modulators
03/13/2008WO2008028690A1 1-(het)aryl-3-[hetaryl-piperidin-4-yl]-thioureas as modulators of the ep2 receptor
03/13/2008WO2008028689A1 N-(1-phthalazin-1-ylpiperidin-4-yl)amides as ep2 receptor modulators
03/13/2008WO2008028662A1 N-[1-(3-amino-4-phenyl-butyryl)-4-hydroxy-pyrrolidin-2-ylmethyl}-propionamide and related compounds as dpp-iv inhibitors for the treatment of type 2 diabetes mellitus
03/13/2008WO2008028635A1 Skin care composition
03/13/2008WO2008028632A1 Skin care composition
03/13/2008WO2008028617A1 Heteroaryl derivatives as protein kinase inhibitors
03/13/2008WO2008028590A1 Novel substituted bipyridine derivatives and their use as adenosine receptor ligands
03/13/2008WO2008028584A1 Preparations for oral administration (i)
03/13/2008WO2008028547A1 Liquid composition for prevention and/or treatment of different bone metabolic diseases, uses thereof, and preparation process therefore
03/13/2008WO2008028427A1 Derivatives of 2-phenyl-3-hydroxyquinoline-4(1h)-one and methods of their preparation and utilization
03/13/2008WO2008028410A1 Use of low molecular weight fucoidan in the preparation of medicament for the treatment of cardiovascular and cerebrovascular diseases
03/13/2008WO2008028405A1 Neukinase, a downstream protein of neuregulin
03/13/2008WO2008028347A1 Combined antibiotics preparation
03/13/2008WO2008028336A1 A pharmaceutical composition of scutellarein and scutellarin or baicalin having synergistical antitumor effect
03/13/2008WO2008028324A1 Novel levamisole formulation for allergic rhinitis
03/13/2008WO2008028314A1 Catechol derivatives, composition and application thereof
03/13/2008WO2008028301A1 Prodrugs of inhibitors of cathepsin s
03/13/2008WO2008028300A1 Oral polymeric membrane feruloyl esterase producing bacteria formulation
03/13/2008WO2008028269A1 Stabilized synthetic brood pheromone for manipulating the behaviour and physiology of honey bees
03/13/2008WO2008028268A1 Diet supplement for causing weight loss comprising cissus quandrangulans, green tea and caffeine
03/13/2008WO2008028267A2 Pantographic-type opening and reading tool kit
03/13/2008WO2008014263A3 Dimeric iap antagonists
03/13/2008WO2008014252A3 Iap inhibitors
03/13/2008WO2008014041A3 Nutritional formulations containing octenyl succinate anahydride-modified tapioca starch
03/13/2008WO2008013985A9 Use of heat shock activators for tissue regeneration
03/13/2008WO2008013860A3 Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use
03/13/2008WO2008013791A3 Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal
03/13/2008WO2008013764A3 Method for prevention and treatment of alzheimers
03/13/2008WO2008012532A3 : pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase
03/13/2008WO2008008837A3 A method of increasing tryptophan and nicotinamide levels in vivo
03/13/2008WO2008008718A3 Cyclopentane derivatives as antiglaucoma agents
03/13/2008WO2008008480A3 Nitroheteroaryl-containing rifamycin derivatives
03/13/2008WO2008008024A9 Polymorphic forms of spirapril hydrochloride
03/13/2008WO2008007149A3 New medical use of triazine derivatives
03/13/2008WO2008006716A3 Improvements relating to pharmaceutical compositions
03/13/2008WO2008005624A3 Method of treatment of hereditary hemochromatosis
03/13/2008WO2008003752A8 2 -amino benzimidazole derivatives and their use as modulators of small - conductance calcium -act ivated potassium channels
03/13/2008WO2008003701A3 Combination of hmg-coa reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases
03/13/2008WO2008003321A3 Compositions with several hyaluronic acid fractions for cosmetic use
03/13/2008WO2008001115A3 Pharmaceutical combinations of 1-cyclopropyl-3- [3- (5-m0rphoolin-4-ylmethyl-1h-benzoimidazol-2-yl) -lh-1-pyrazol- 4-yl] -urea
03/13/2008WO2007150063A3 Compositions for lowering blood serum cholesterol and use in foods, beverages, and health supplements
03/13/2008WO2007148185A3 Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
03/13/2008WO2007148116A3 Topical pharmaceutical formulations
03/13/2008WO2007148102A3 Crystalline duloxetine hydrochloride
03/13/2008WO2007147899A3 Dha esters and use thereof in treatment and prevention of cardiovascular disease
03/13/2008WO2007147590A3 Solution and method to reduce, treat and/or prevent oxidative stress and cell activation
03/13/2008WO2007147372A3 Pharmaceutical composition for administration by injection
03/13/2008WO2007146547A3 Piperazine enamines as antiviral agents
03/13/2008WO2007146416A3 Glucan preparations
03/13/2008WO2007146376A3 Substituted 3-cyanopyridines as protein kinase inhibitors
03/13/2008WO2007144530A3 Free-radical-scavenger cosmetic composition
03/13/2008WO2007144422A3 Combination preparations comprising bifeprunox and l-dopa
03/13/2008WO2007144323A3 Solid forms containing meloxicam with improved taste and process for their preparation
03/13/2008WO2007144153A3 Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
03/13/2008WO2007142811A3 Low dose doxepin formulations, including buccal, sublingual and fastmelt formulations, and uses of the same to treat insomnia
03/13/2008WO2007142810A3 Methods of using low-dose doxepin for the improvement of sleep
03/13/2008WO2007139886A3 Duloxetine hydrochloride delayed release formulations
03/13/2008WO2007137200A3 Phosphorous containing compounds including triphenylmethylphosphonate esters for the treatment of melanoma and other cancers
03/13/2008WO2007136845A3 Low-dose doxepin for treatment of sleep disorders in elderly patients
03/13/2008WO2007136570A3 5,6-fused pyrrolidine compounds useful as tachykinin receptor antagonists
03/13/2008WO2007136302A8 Active substances, pharmaceutical composition and a method for the production and use thereof
03/13/2008WO2007136116A3 C-phenyl glycitol compound for the treatment of diabetes
03/13/2008WO2007135527A3 Benzimidazolyl compounds
03/13/2008WO2007135123A3 Mirtazapine for the treatment of neuropathic pain
03/13/2008WO2007133352A3 Macrocyclic kinase inhibitors
03/13/2008WO2007130820A3 Mglur5 modulators i
03/13/2008WO2007129329A3 Extended release pharmaceutical formulation comprising venlafaxine hydrochloride
03/13/2008WO2007129114A3 Aptamers directed to recombinant muc1
03/13/2008WO2007127635A3 Diketo-piperazine and piperidine derivatives as antiviral agents
03/13/2008WO2007125310A3 Pharmaceutical combinations of pk inhibitors and other active agents
03/13/2008WO2007123939A8 Novel arylamino n-heteraryls as mek inhibitors
03/13/2008WO2007123400A9 Vaccine against nicotine addiction
1 ... 3340 3341 3342 3343 3344 3345 3346 3347 3348 3349 3350 3351 3352 3353 3354 3355 3356 3357 3358 3359 3360 ... 7860